M&A / Deals Lilly puts up to $2.75bn into Insilico alliance PharmaphorumInsilico has once again added to its roster of big pharma partners, signing a deal with Eli Lilly that includes a $115m upfront payment.M&A / DealsRead full story pharminent March 29, 2026 (Last updated: March 30, 2026) Pharmaphorum Insilico has once again added to its roster of big pharma partners, signing a deal with Eli Lilly that includes a $115m upfront payment. M&A / DealsRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: S16 Ep38: Live Tumor Board: Precision Pathways Transforming Patient Care in Advanced NSCLCNext: Otsuka grows in neuroplastogens with $1.225bn Transcend buy Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
